Showing 4331-4340 of 9152 results for "".
- James P. Hartman Named New Vice President and General Manager at Solta Medicalhttps://practicaldermatology.com/news/james-p-hartman-named-new-vice-president-and-general-manager-at-solta-medical/2458011/James P. Hartman is the new Vice President and general manager at Solta Medical, a division of Valeant Pharmaceuticals North America LLC. Mr. Hartman joined Solta Medical from Merz Aesthetics (a division of Merz Pharm
- Eau Thermale Avène Expands its #AveneHope Programhttps://practicaldermatology.com/news/eau-thermale-avne-expands-its-avenehope-program/2458015/In recognition of Eczema Awareness Month and National Bullying Prevention Awareness Month this October, Eau Thermale Avène is expanding its #AveneHope program to
- ASDS Elects New Officers, Board Membershttps://practicaldermatology.com/news/asds-elects-new-officers-board-members/2458016/The American Society for Dermatologic Surgery (ASDS) introduced their new Vice Presid
- Meet Thermage's New FLX Systemhttps://practicaldermatology.com/news/meet-thermages-new-flxtm-system/2458026/The US Food and Drug Administration granted 510(K) clearance to Solta Medical’s new Thermage FLXTM System for smoothing skin on the face, eyes, and body. The Thermage FLX features a new optimized energy delivery algorithm, know
- SmartGraft Taps Industry Vet as New EVPhttps://practicaldermatology.com/news/smartgraft-taps-new-evp/2458031/Joseph R. Brown is the new Executive Vice President for SmartGraft®, a minimally invasive hair restoration
- Novan Has Guidance Meeting with FDA on SB204https://practicaldermatology.com/news/novan-has-guidance-meeting-with-fda-on-sb204/2458040/Novan, Inc. is eyeing an additional pivotal trial for its investigational treatment for acne vulgaris, SB204. The company concluded a guidance meeting with the FDA regarding SB204 in which the agency advised that an additional pivotal trial should be conducted. Given the need for the ad
- Update from DFB Soria on Enrollment in Phase 2 Clinical Trial of Nanoparticle Paclitaxel Ointment for AKhttps://practicaldermatology.com/news/update-from-dfb-soria-on-enrollment-in-phase-2-clinical-trial-of-nanoparticle-paclitaxel-ointment-for-ak/2458039/DFB Soria, a clinical-stage pharmaceutical development company, and an affiliate of NanOlogy™, completed the second of four patient cohorts enrolled in a Phase 2 actinic keratosis (AK) clinical trial of a topical ointment containing nanoparticle
- New Data: Aclaris' A-101 40% Safely Banishes Facial SK Lesionshttps://practicaldermatology.com/news/new-data-aclaris-a-101-40-safely-banishes-facial-sk-lesions/2458044/Good news for Aclaris. New data suggest that their drug candidate A-101 40 percent may be an appealing option to remove seborrheic keratosis (SK) lesions in highly visible areas, such as the face, with minimal risk of s
- New Label Reflects Sustained Response for Sun Pharma's Odomzo in BCChttps://practicaldermatology.com/news/new-label-reflects-sustained-response-for-sun-pharmas-odomzo-in-bcc/2458045/Sun Pharma’s new Odomzo® (Sonidegib) label incorporates long-term data showing sustained duration of response of 26 months in treatment of locally advanced basal cell carcinoma. Odomzo® is an oral hedgehog inhibitor indicated for t
- Eva Genel Named Director of Research and Development, Skincare at Silk Therapeuticshttps://practicaldermatology.com/news/eva-genel-named-director-of-research-and-development-skincare-at-silk-therapeutics/2458047/Eva Genel is the new Director of Research and Development, Skincare at Silk Therapeutics Inc., a specialty biomaterials company. In this new role, Genel's key responsibilities include designing and assessing clean, skincare formulations, o